Chardan Capital Reiterates Buy on Iovance Biotherapeutics, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $29.
August 16, 2023 | 4:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Iovance Biotherapeutics and maintained a price target of $29.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Iovance Biotherapeutics. The maintained price target of $29 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100